Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics

Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members

doi:10.1016/S0140-6736(21)00242-7

Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics

Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	562-564
Number of pages	3
Journal	The Lancet
Volume	397
Issue number	10274
DOIs	https://doi.org/10.1016/S0140-6736(21)00242-7
State	Published - Feb 13 2021

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(21)00242-7

Cite this

@article{4ebb05f96ad243daa1d30464c301c88c,

title = "Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics",

author = "{Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members} and Figueroa, {J. Peter} and Bottazzi, {Maria Elena} and Peter Hotez and Carolina Batista and Onder Ergonul and Sarah Gilbert and Mayda Gursel and Mazen Hassanain and Kim, {Jerome H.} and Bhavna Lall and Heidi Larson and Denise Naniche and Timothy Sheahan and Shmuel Shoham and Annelies Wilder-Smith and Natalie Strub-Wourgaft and Prashant Yadav and Gagandeep Kang",

note = "Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd, a commercial vaccine manufacturer for scale-up, production, testing, and licensure. JPF and GK are members of the WHO SAGE Working Group on COVID-19 vaccines. SG has a ChAdOx1 nCoV-19 patent application licensed to AstraZeneca. MH is Founder and Managing Director of SaudiVax. JHK reports personal fees from SK biosciences. GK is an Independent Director of Hilleman Laboratories Private Limited and Vice Chair of the Board of CEPI. HL reports grants and honoraria for training talks from GlaxoSmithKline, and grants and honoraria from Merck as a member of the Merck vaccine confidence advisory board, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Diseases, research contracts from GlaxoSmithKline, research contracts from ViiV Healthcare, and grants from Fast Grants. SS reports grants from the US Department of Defense, Bloomberg Foundation, State of Maryland, Ansun, Astellas, Cidara, F2G, T2, Shire, Shionogi, and Scynexis; personal fees from Acidophil, Amplyx, Janssen, Karyopharm, Intermountain Health, and Immunome; grants and personal fees from Merck, Reviral outside the submitted work. All other authors declare no competing interests. The authors' views and opinions in this Comment do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated. We thank Jeffrey Sachs, Chair of the Lancet COVID-19 Commission, and Yanis Ben Amor, member of the Secretariat of this Commission, for their invaluable review and feedback. ",

year = "2021",

month = feb,

day = "13",

doi = "10.1016/S0140-6736(21)00242-7",

language = "English (US)",

volume = "397",

pages = "562--564",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10274",

}

TY - JOUR

T1 - Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics

AU - Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members

AU - Figueroa, J. Peter

AU - Bottazzi, Maria Elena

AU - Hotez, Peter

AU - Batista, Carolina

AU - Ergonul, Onder

AU - Gilbert, Sarah

AU - Gursel, Mayda

AU - Hassanain, Mazen

AU - Kim, Jerome H.

AU - Lall, Bhavna

AU - Larson, Heidi

AU - Naniche, Denise

AU - Sheahan, Timothy

AU - Shoham, Shmuel

AU - Wilder-Smith, Annelies

AU - Strub-Wourgaft, Natalie

AU - Yadav, Prashant

AU - Kang, Gagandeep

N1 - Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd, a commercial vaccine manufacturer for scale-up, production, testing, and licensure. JPF and GK are members of the WHO SAGE Working Group on COVID-19 vaccines. SG has a ChAdOx1 nCoV-19 patent application licensed to AstraZeneca. MH is Founder and Managing Director of SaudiVax. JHK reports personal fees from SK biosciences. GK is an Independent Director of Hilleman Laboratories Private Limited and Vice Chair of the Board of CEPI. HL reports grants and honoraria for training talks from GlaxoSmithKline, and grants and honoraria from Merck as a member of the Merck vaccine confidence advisory board, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Diseases, research contracts from GlaxoSmithKline, research contracts from ViiV Healthcare, and grants from Fast Grants. SS reports grants from the US Department of Defense, Bloomberg Foundation, State of Maryland, Ansun, Astellas, Cidara, F2G, T2, Shire, Shionogi, and Scynexis; personal fees from Acidophil, Amplyx, Janssen, Karyopharm, Intermountain Health, and Immunome; grants and personal fees from Merck, Reviral outside the submitted work. All other authors declare no competing interests. The authors' views and opinions in this Comment do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated. We thank Jeffrey Sachs, Chair of the Lancet COVID-19 Commission, and Yanis Ben Amor, member of the Secretariat of this Commission, for their invaluable review and feedback.

PY - 2021/2/13

Y1 - 2021/2/13

UR - http://www.scopus.com/inward/record.url?scp=85101028214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101028214&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(21)00242-7

DO - 10.1016/S0140-6736(21)00242-7

M3 - Comment/debate

C2 - 33516284

AN - SCOPUS:85101028214

SN - 0140-6736

VL - 397

SP - 562

EP - 564

JO - The Lancet

JF - The Lancet

IS - 10274

ER -

Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this